Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Bioniche rallies on debt refinancing news

Stockhouse Editorial
0 Comments| July 5, 2013


Bioniche Life Sciences Inc. (TSX: T.BNC, Stock Forum) and Paladin Labs Inc. (TSX: T.PLB, Stock Forum) on Friday announced the official closing of the various agreements associated with a comprehensive strategic collaboration to refinance and increase Bioniche’s debt, provide new equity and enter into the first licensing deal for Bioniche’s Phase 111 bladder cancer project – Urocidin.

The closing of the deal has resulted in the issuance of a further $5 million in debt financing to Bioniche from Paladin, the companies said in a press release.

Bioniche rose 8% to 33 cents Friday, leaving the company with a market cap of $35 million, based on 105.4 million shares outstanding. The 52-week range is 69 cents and 18 cents.

Paladin was up 0.16% to $56.31, leaving a market cap of $1.16 billion, based on 20.6 million shares outstanding. The 52-week range is $58.25 and $39.01.

Tags: BIOTECHNOLOGY DRUG MANUFACTURERS - SPECIALTY & GENERIC SHARES 52-WEEK

Rate this article
3 stars
v
Usefulness

Clarity

Credibility

Comments

No comments yet. Be first to comment!

Leave a Message

You must be logged in to access this feature.